TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.

Trial Details

NCT ID
NCT04701476
Phase
PHASE2
Sponsor
Teclison Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • TATE and pembrolizumab
  • TAS-102 pill
  • Regorafenib Pill
Locations (sample)
  • Orange, California, United States|33.78779,-117.85311
  • Hsinchu, Taiwan|24.80361,120.96861
  • Taichung, Taiwan|24.1469,120.6839

Key Eligibility Criteria

  • Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
  • mCRC progressed on at least two lines of standard chemotherapy; or
  • NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
  • Measurable disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →